Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

27 Aug 2012

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

n order to find out what kind of doctor patients were visiting for primary care service, researchers analyzed the frequency in which patients visited generalists and specialists in 1999 and 2007 by using a nationally representative sample of outpatient visits.

26 Aug 2012

Survival rate for African-American men with prostate cancer now comparable to Caucasians

The routine use of prostate specific antigen (PSA) testing for screening and monitoring prostate cancer has led to early and more sensitive detection of the disease. A new study published in The Journal of Urology- reports that in the "PSA era," survival has improved for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body and the disparity between African American and Caucasian men has been resolved.

24 Aug 2012

Study shows how cancer survival rates developed in West Germany

Data from the 1970s and 1980s show that people affected by cancer survived significantly longer in West Germany than cancer patients behind the Iron Curtain.

24 Aug 2012

Racial differences persist in prostate cancer surgical care

A study led by investigators from Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tenn., finds that black men with prostate cancer receive lower quality surgical care than white men. The racial differences persist even when controlling for factors such as the year of surgery, age, comorbidities and insurance status.

24 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

Fizzy tablet is best method to receive fentanyl for cancer pain

Results of a mixed treatment comparison show that fentanyl in the form of an effervescent buccal tablet can better relieve the intensity of breakthrough cancer pain in the first 60 minutes after dosing compared with other fentanyl formulations.

23 Aug 2012

Six common myths about prostate cancer

When it comes to prostate cancer, there's a lot of confusion about how to prevent it, find it early and the best way - or even whether - to treat it. Below are six common prostate cancer myths along with research-based information from scientists at Fred Hutchinson Cancer Research Center to help men separate fact from fiction.

23 Aug 2012

‘Sitting service’ at end of life may improve chances of dying at home

Individuals at the end of their life who use a sitting service to avoid being alone while dying or to give respite to family members who are caring for them, are significantly more likely to die at home than those who do not use such a service, report researchers.

22 Aug 2012

Viewpoints: Insuring medical treatments are well researched; GOP Govs reluctance on exchanges may backfire

By 1990, many doctors were recommending hormone replacement therapy to healthy middle-aged women and P.S.A. screening for prostate cancer to older men. Both interventions had become standard medical practice. But in 2002, a randomized trial showed that preventive hormone replacement caused more problems (more heart disease and breast cancer) than it solved. ... Then, in 2009, trials showed that P.S.A. screening led to many unnecessary surgeries and had a dubious effect on prostate cancer deaths.

21 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

Safety net hospitals prepare for changes from health law; Patients hesitant to challenge doctors

Safety-net hospitals – which often provide care to low-income and uninsured populations – are facing reduced federal and state support for uncompensated care under the Affordable Care Act. However, this study points out that 23 million people will remain uninsured and continue to need care from the hospitals.

18 Aug 2012

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

The European Society for Medical Oncology (ESMO) announced today the names of two eminent cancer specialists and one European institution that will be recognized for their contribution to the advancement of medical oncology at the ESMO 2012 Congress.

17 Aug 2012

Pan-fried red meat associated with increased risk of advanced prostate cancer

Research from the University of Southern California (USC) and Cancer Prevention Institute of California (CPIC) found that cooking red meats at high temperatures, especially pan-fried red meats, may increase the risk of advanced prostate cancer by as much as 40 percent.

17 Aug 2012

Enzalutamide drug extends survival in people with advanced prostate cancer

Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.

17 Aug 2012

Targets to improve palliative patients’ wellbeing identified

Pain, depression, drowsiness, fatigue, and appetite loss are the symptoms that most affect the wellbeing of cancer patients being treated palliatively, report Canadian researchers.

16 Aug 2012

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend life.

16 Aug 2012

Cancer patients with xerostomia can benefit from regenerative research

Biologists, surgical oncologists and regenerative medicine specialists from Rice University, the University of Delaware and the Christiana Care Health System in Wilmington, Del., have begun a four-year program aimed at using cells to grow whole salivary glands that can replace those destroyed by cancer radiation therapy.

16 Aug 2012

Mechanism for chemotherapy resistance identified

Researchers have identified that chemotherapy induces subsequent treatment resistance through damaging healthy tissue, which in turn secretes novel factors that sustain the growth of residual tumor cells.

15 Aug 2012

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Eplerenone shown to reduce cumulative heart failure hospitalisations

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

Survival rate for African-American men with prostate cancer now comparable to Caucasians

Study shows how cancer survival rates developed in West Germany

Racial differences persist in prostate cancer surgical care

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Fizzy tablet is best method to receive fentanyl for cancer pain

Six common myths about prostate cancer

‘Sitting service’ at end of life may improve chances of dying at home

Viewpoints: Insuring medical treatments are well researched; GOP Govs reluctance on exchanges may backfire

Enzalutamide extends castration-resistant prostate cancer survival

Safety net hospitals prepare for changes from health law; Patients hesitant to challenge doctors

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

Pan-fried red meat associated with increased risk of advanced prostate cancer

Enzalutamide drug extends survival in people with advanced prostate cancer

Targets to improve palliative patients’ wellbeing identified

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

Cancer patients with xerostomia can benefit from regenerative research

Mechanism for chemotherapy resistance identified

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in